Skip to main content
Tufts Public Health

Michael Schatman

Adjunct Clinical Assistant Professor of Public Health and Community Medicine
​Director of Research and Network Development, Boston Pain Care
Editor-in Chief, Journal of Pain Research
Programs: Pain Research Education and Policy

Michael Schatman

Adjunct Clinical Assistant Professor of Public Health and Community Medicine
​Director of Research and Network Development, Boston Pain Care
Editor-in Chief, Journal of Pain Research
Programs: Pain Research Education and Policy

Phone ​617-636-7000
Campus: Boston

Education

  • ​Ph.D. in Counseling Psychology, University of North Texas, Denton, Texas, 1989.
  • M.S. in General Psychology from the University of North Texas, Denton, Texas, 1985.
  • B.A. from Columbia University, New York, New York, 1981.

Research synopsis

Pain Bioethics, Opioid Risk Mitigation, Cannabinoid Medicine, Pain Education

Publications

(Selected from 2010 and later)

  1. Robinson JP, Leo R, Wallach J, McGough E. Schatman ME. Rehabilitative treatment for chronic pain. In: Stannard C, Kalso E, Ballantyne JC, eds. Evidence-Based Chronic Pain Management. Oxford, UK: Blackwell Publishing, 2010;407-423.
  2. Schatman ME. Interdisciplinary chronic pain management: perspectives on history, current status, and future viability. In: Ballantyne JC, Rathmell JP, Fishman SM, eds. Bonica's Management of Pain, 4th edition. Philadelphia: Lippincott, Williams & Wilkins, 2010;1523-1532.
  3. Schatman ME, Gatchel RJ. Introduction to special issue on traumatically-induced pain: assessing and addressing controversies. Psychological Injury and Law, 2010;3:165-168.
  4. Schatman ME, Sullivan J. Whither suffering? The potential impact of tort reform on the emotional and existential healing of traumatically injured chronic pain patients. Psychological Injury and Law, 2010;3:182-202.
  5. Schatman ME. Psychological assessment of maldynic pain: the need for a phenomenological approach. In: Giordano J, ed. Maldynia: Inter-disciplinary Perspectives on the Illness of Chronic Pain. New York: Informa Healthcare, 2010;157-182.
  6. Schatman ME, Lebovits AH. On the transformation of the "profession" of pain medicine to the "business" of pain medicine: an introduction to a special series. Pain Med. 2011;12:403-405.
  7. Schatman ME. The role of the health insurance industry in perpetuating suboptimal pain management: ethical implications. Pain Med. 2011;12:415-426.
  8. Schatman ME. Misconceptions, challenges, and realities in assessing pain in cognitively impaired older patients. Painview 2011;7:4-8.
  9. Giordano J, Schatman ME. Pain Medicine from "bench to bedside": bridging the disconnect(s) between research and clinical care. J Healthc Sci Humanit. 2011;1:22-41.
  10. Schatman ME. Editorial: Pain and corporatization: more special interests, more disparities, more vulnerability. Pain Med. 2011;12:632-633.
  11. Schatman ME. Pain medicine: profession or business? Medscape Neurology 2011. Available at: http://www.medscape.com/viewarticle/742692.
  12. Schatman ME. Editorial: Special interests in pain medicine: then, now, and forever? Pain Med. 2011;12:1060-1062.
  13. Schatman ME. Editorial: The suppression of evidence-basis in pain medicine and the physician-driven quest to re-establish It. Pain Med. 2011;12:1358-1360.
  14. Schatman ME. The medical-industrial complex and conflict of interest in pain education. Pain Med. 2011;12:1710-1712.
  15. Campbell LC, Robinson K, Meghani SH, Vallerand A, Schatman M, Sonty N. Challenges and opportunities in pain management disparities research: implications for clinical practice, advocacy and policy. J Pain 2012;13:611-619.
  16. Schatman ME. Physician complicity in the transformation of pain medicine from a profession to a business: strategies for reversing a growing trend. Pain Med. 2012;13:1149-1151.
  17. Schatman ME. Medical cannabis: the ethical conundrum associated with recreational "legalization" of marijuana. Medscape Neurology 2012. Available at: http://www.medscape.com/viewarticle/774482.
  18. Schatman ME. Interdisciplinary chronic pain management: international perspectives. Pain: Clin Updates 2012:20(7):1-5.
  19. Schatman ME. Balancing continuing medical education and conflict of interests in pain medicine: an ethical imperative. Pain Med. Network 2012;27:10-11.
  20. Schatman ME. Workers' compensation and its potential for perpetuation of disability. In: Gatchel RJ, Schultz I, (eds.). Handbook of Occupational Health and Wellness. New York: Springer, 2013:341-361.
  21. Darnall BD, Schatman ME, Argoff CE, Ballantyne JB. Understanding opioids: Part 1. Medscape Neurology 2013. Available at: http://www.medscape.com/viewarticle/777126.
  22. Schatman ME, Darnall BD. The resurrection of the Ethics Forum in Pain Medicine: an introduction. Pain Med. 2013;14:453-454.
  23. Schatman ME. Medical cannabinoids for the treatment of chronic pain: the ethical imperative for consideration. Painview 2013;9:21-27.
  24. Schatman ME, Darnall BD. A pendulum swings awry: seeking the middle ground on opioid prescribing for chronic non-cancer pain. Pain Med. 2013;14:617-620.
  25. Schatman ME, Darnall BD. Medical marijuana: a viable tool in the armamentaria of physicians treating chronic pain? A case study and commentary. Pain Med. 2013;14:799-801.
  26. Darnall BD, Schatman ME. Autonomy vs. paternalism in the emergency department: the deleterious impact of patient satisfaction surveys. Pain Med. 2013:14:968-970.
  27. Schatman ME. Medical marijuana: the imperative of educating physicians. Medscape Neurology 2013. Available at: http://www.medscape.com/viewarticle/810356_2.
  28. Schatman ME, Darnall BD. Upscheduling of hydrocodone: convenience and access vs. patient safety measures. Pain Med. 2013;14:1627-1630.
  29. Schatman ME, Darnall BD. "Just Saying No" to mandatory pain CME: how important is physician autonomy? Pain Med. 2013;14:1821-1825.
  30. Schatman ME, Darnall BD. A practical and ethical solution to the opioid scheduling conundrum. J Pain Res. 2014;7:1-3.
  31. Schatman ME, Darnall BD, Trescot A, Cohen SP. The needle and the damage done? Pain Med. 2014;15:544-547.
  32. Atkinson TJ, Schatman ME, Fudin J. The damage done by the war on opioids: the pendulum has swung too far. J Pain Res. 2014;7:265-268.
  33. Schatman ME, Thoman J. Erratum to: Cherry-picking records in independent medical examinations: a legal and ethical imbroglio. Psychological Injury and Law 2014;7:290-295.
  34. Schatman ME, Darnall BD, Loeser JD, Deer TR. Intrathecal opioids for chronic nonmalignant pain: a case study and the search for balance. Pain Med. 2014;15:1268-1271.
  35. Carter GT, Schatman ME. Editorial: What is the evidence base for electronic medical records improving quality in hospice and palliative medicine? Am J Hosp Palliat Med. 2014;31:697-698.
  36. Darnall BD, Schatman ME, Compton P, Goldberg DS, Rich BA. Urine drug screening: necessary or alienating? Pain Med. 2014;15:1999-2002.
  37. Schatman ME, Darnall BD, Verdolin MH, Loeser JD, Deer TR, Doleys DM, Hamza M. Reader responses to the ethics forum: room for multiple perspectives. Pain Med. 2015;16:18-24.
  38. Schatman ME. Medical marijuana: the state of the science. Medscape Neurology 2015. Available at: http://www.medscape.com/viewarticle/839155.
  39. Gholizadeh S, Malcarne VL, Schatman ME. Ethical quandaries for psychologists in workers' compensation settings: the GAF gaffe. Psychological Injury and Law 2015;8:64-81.
  40. Schatman ME, Webster LR. The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. J Pain Res. 2015;8:153-158.
  41. Darnall BD, Schatman ME, Carroll IR, Dalal PG. Opioid use and lactation: protecting the child in the context of maternal pain care. Pain Med. 2015;16:628-632.
  42. Darnall BD, Schatman ME, Schofferman J, Stanton M. The relationship between industry and pain societies, part 1: demystification and legitimization of continuing medical education. Pain Med. 2015;16:1251-1255.
  43. Washington State Agency Medical Directors' Group (AMDG) in collaboration with an Expert Advisory Panel, Actively Practicing Providers, Public Stakeholders, and Senior State Officials (Schatman ME – contributing author). Interagency Guideline on Prescribing Opioids for Pain 2015. Available at: http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf.
  44. Schatman ME. Medical marijuana and neuromysticism: the data spell the beginning of the end. Painview 2015;11:24-25.
  45. Schatman ME. Medical use of cannabinoids. JAMA. 2015;314:1751.
  46. Schatman ME, Thoman JL. Valid psychological injury claims: respecting the needs of survivors. Psychological Injury and Law, 2015;8:311-322.
  47. Schatman ME. The American chronic pain crisis and the media: about time to get it right? J Pain Res. 2015;8:885-887.
  48. Peppin JF, Schatman ME. Terminology of chronic pain: the need to "level the playing field". J Pain Res. 2016;9:23-24.
  49. Schatman ME, Darnall BD, Wallace MS, Rothman DJ. Conflict of interest, part II: pain society leadership and industry. Pain Med. 2016;17:217-219.
  50. Fudin J, Pratt Cleary J, Schatman ME. The MEDD myth: the impact of pseudoscience on pain research and prescribing guideline development. J Pain Res. 2016;9:153-156.
  51. Brady MP, Schatman ME. Medical marijuana: a view beyond the smoke. Medscape Drugs & Diseases 2016. Available at: http://reference.medscape.com/features/slideshow/med-marijuana#page=1.
  52. Schatman ME. A glimmer of hope in American pain medicine? J Pain Res. 2016;9:509-513.
  53. Savage SS, Romero-Sandoval A, Schatman ME, Wallace M, Fanciullo G, McCarberg W, Ware M. Cannabis in pain treatment: clinical and research implications. J Pain 2016;17:654-658.
  54. DeGregori M, Scotti V, De Silvestri A, Curti M, Fanelli G, Allegri M, Schatman ME. Does research group increase impact on the scientific community or general public discussion? Alternative metric-based evaluation. J Pain Res. 2016;9:391-395.
  55. Fudin J, Atkinson TJ, Raouf M, Schatman ME. Can we not work together to help family practitioners become more effective pain managers? J Pain Res. 2016;9:803-806.
  56. De Gregori M, Muscoli C, Schatman ME, et al. Combining pain therapy with lifestyle: the role of personalized nutrition and nutritional supplements according to the SIMPAR Feed Your Destiny approach. J Pain Res. 2016;9:1179-1189.
  57. Compagnone C, Schatman ME, Rauck R, Van Zundert J, Kraus M, Primorac D, et al. Past, present, and future of informed consent in pain and genomics research: challenges facing global medical community. Pain Pract. 2016 [Epub ahead of print].
  58. Schatman ME, Fudin J. The myth of morphine equivalent daily dosage. Medscape Neurology 2016. Available at: http://www.medscape.com/viewarticle/863477.
  59. Gholizadeh D, Malcarne VL, Schatman ME. Functioning well in a dysfunctional system: recommendations for clinical psychologists in workers' compensation settings. Psychological Injury and Law 2016;9:360-375.
  60. Fudin J, Wegrzyn EL, Raouf M, Schatman ME. An Important View on Pain as a 5th Vital Sign. Pains Project Policy and Education Brief 2017;8:1-8.
  61. Keppel Hesselink J, Schatman ME. EMA401: an old antagonist of the angiotensin II type 2 receptor (AT2R) for a new indication: neuropathic pain. J Pain Res. 2017;10:439-444.
  62. Schatman ME, Benitez OJ. Adherence in pain medicine: ethical issues. In: Cheatle M, Fine P (eds.). Facilitating Treatment Adherence in Pain Medicine. New York: Oxford University Press, 2017;158-181.
  63. Loeser JD, Schatman ME. Chronic pain management in medical education: a disastrous omission. Postgrad Med. 2017;129:332-335.
  64. Fanelli G, De Carolis G, Leonardi C, Longobardi A, Allegri M, Schatman ME. Cannabis and intractable chronic pain: Italian case series of 614 patients. J Pain Res. 2017;10:1217-1224.
  65. Keppel Hesselink J, Schatman ME. Phenytoin and carbamazepine in trigeminal neuralgia: marketing-based versus evidence-based treatment. J Pain Res. 2017;10:1663-1666.
  66. Darnall BD, Carr DB, Schatman ME. Pain psychology and the biopsychosocial model of pain treatment: ethical imperatives and social responsibility. Pain Med. 2017;18:1413-1415.
  67. DiBenedetto DJ, Weed V, Wawrzyniak KM, Finkelman M, Paolini J, Schatman ME, Herrera D, Kulich RJ. The association between cannabis use and aberrant behaviors during chronic opioid therapy for chronic pain. Pain Med. 2017 (in press).
  68. Schatman ME. The demise of interdisciplinary chronic pain management and its relationship to the scourge of prescription opioid diversion and abuse. In: Peppin J, Kirsh K, Coleman J (eds.). Pain and Prescription Drug Diversion: Healthcare, Law Enforcement, and Policy Perspectives. New York: Oxford University Press, 2017 (in press).
  69. Schatman ME. Corporate commoditization in pain medicine: increased profits translate to increased suffering. In Giordano J (ed.). Augmenting Human Painlessness. New York: Springer, 2017 (in press).